COMPASS Pathways (CMPS)
(Delayed Data from NSDQ)
$6.21 USD
+0.32 (5.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CMPS 6.21 +0.32(5.43%)
Will CMPS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CMPS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CMPS
COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
CMPS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
Other News for CMPS
Rising High: RIV Capital, Cansortium launch MOODS brand in New York
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
Rising High: Village Farms acquires remaining interest in Leli Holland
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning